The Bottom Line: Interim CEO, Dan Orlando brings a depth of experience in the development and commercialization of cardiovascular and metabolic therapies that will help ASTM to continue moving forward. Mr. Mayleben will continue to support the transition to a permanent CEO. I am not the only one to say – “Great Move”; Steve Brozak of WBB Securities also signaled the same message in a call … “Dan past deal structure successes and experience should further focus … ASTM’s ability to drive significant value to this disease state franchise”! ASTM closed DOWN yesterday … at $1.30 but, is up $0.02 to $1.32 at the open with a tighter mid-day range of $1.29 – $1.32 but, is settling at $1.30. I have NOT given up as ASTM has been getting “hammered” on filings of stock sales but, they are … related to the warrant swaps … which other companies have been … unable … to recognize with their “muddied” balance sheets! I have maintained a “BUY” in this market and at this pricing because of the late stage trial status even with a dwindling RegMed universe pricing and visibility. As the BOD … fulfills its responsibility … they will make this appointment permanent in the New Year !
One must remember that ole Henry is as clueless as they come! As long as ASTM keeps paying him he will say anything even if he knows it's #$%$! Pay no attention to the expert at cut & paste posting! He has never written an original word in his lifetime!
It's difficult to take a poster serious when he can't even spell. Your like the kid in the back seat asking if we're there yet. The board thinks your a gay buffone posting between impaleings from a trailer along HWY 1.